NCT01258764

Brief Summary

The purpose of this trial is to evaluate if an objective clinical decision of anti-hypertensive therapy can be made using an N-of-1 (single patient) trial design.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2010

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 9, 2010

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 13, 2010

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2014

Completed
Last Updated

May 20, 2015

Status Verified

May 1, 2015

Enrollment Period

3.3 years

First QC Date

December 9, 2010

Last Update Submit

May 19, 2015

Conditions

Keywords

hypertensionBlood Pressure controlhypertension treatmentantihypertensiveN of 1 study

Outcome Measures

Primary Outcomes (1)

  • Blood pressure control defined as 24-hour ambulatory systolic and diastolic pressure average below 135/85 mmHg.

    After 14 week study period with assessment of patient specific data

Secondary Outcomes (1)

  • Blood Pressure (BP) load, treatment of non-dippers, side effects, and compliance.

    After 14 week study period with assessment of patient specific data

Study Arms (2)

Lisinopril

ACTIVE COMPARATOR
Drug: Lisinopril

Hydrochlorothiazide

ACTIVE COMPARATOR
Drug: Hydrochlorothiazide

Interventions

Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle

Also known as: Prinivil, Zestril, ACE inhibitor
Lisinopril

Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle

Also known as: Aquazide H, Carozide, Diaqua, Esidrix, Ezide, Hydro Par, HydroDIURIL, Hydrocot, Hydrokraft, Loqua, Oretic, Thiazide, HCTZ
Hydrochlorothiazide

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of Grade 1 Hypertension
  • Treatment naïve
  • GFR \> 60 within previous 3 months
  • Urinary microalbumin level normal during previous 3 months

You may not qualify if:

  • Pregnancy (Fetal morbidity and mortality may occur with the use of ACE inhibitors.)
  • Uncontrolled Hyperthyroidism
  • Sleep Apnea
  • Primary Aldosteronism
  • Renovascular Disease
  • Cushing's Syndrome or steroid therapy
  • No evidence of end organ damage
  • EKG with evidence of LVH within previous 3 months
  • Collagen Vascular Disease
  • Current Smoker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Scripps Clinic

La Jolla, California, 92037, United States

Location

Related Links

MeSH Terms

Conditions

HypertensionLymphoma, Follicular

Interventions

LisinoprilAngiotensin-Converting Enzyme InhibitorsHydrochlorothiazideThiazides

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

DipeptidesOligopeptidesPeptidesAmino Acids, Peptides, and ProteinsProtease InhibitorsEnzyme InhibitorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesChlorothiazideBenzothiadiazinesSulfonamidesSulfonesSulfur CompoundsOrganic ChemicalsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Bradley Patay, MD

    Scripps Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Scripps Translational Science Institute

Study Record Dates

First Submitted

December 9, 2010

First Posted

December 13, 2010

Study Start

November 1, 2010

Primary Completion

March 1, 2014

Study Completion

March 1, 2014

Last Updated

May 20, 2015

Record last verified: 2015-05

Locations